Skip to main content

Ionis Pharmaceuticals, Inc.

corporate_fare Company Profile

Ionis Pharmaceuticals, Inc.

IONS·NASDAQ·Life Sciences·CIK 0000874015

Our Company invents medicines for people with serious diseases, focusing on RNA-targeted therapies. We operate as a fully integrated commercial-stage biotechnology company with seven marketed medicines. TRYNGOLZA (olezarsen) is approved in the U.S. as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), in the EU for patients with genetically confirmed FCS, and in Canada. It is the first FDA-approved treatment to significantly reduce triglyceride levels and provide clinically meaningful reduction in acute pancreatitis events in adults with FCS when used with an appropriate diet (≤20 grams of fat per day). We independently commercialize TRYNGOLZA in the U.S. DAWNZERA (donidalorsen) is approved in the U.S. for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older, and in the EU for the routine prevention of recurrent attacks of HAE in the same age group. It is the first and only approved RNA-targeted prophylactic therapy for HAE. We independently commercialize DAWNZERA in the U.S. WAINUA (eplontersen) is approved in the U.S., EU, China, and numerous other countries for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. WAINUA is the only approved medicine for ATTRv-PN that can be self-administered via an auto-injector. We and AstraZeneca co-develop WAINUA globally and co-commercialize it in the U.S. Our other marketed medicines include SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen), and WAYLIVRA (volanesorsen).

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 43 items for IONS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-17, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for IONS spans 10-Q, 8-K.

Recent high-impact activity:

  • Diranersen Slows Alzheimer's Decline Further at Two Years, 38% on CDR-SB
  • EU Regulators Grant TRYNGOLZA Broader Approval in Severe Hypertriglyceridemia
  • Ionis Cuts TRYNGOLZA 2026 Guidance to ~$50M as Q3 Loss Widens
  • Ionis Slashes 2026 Tryngolza Guidance, Shares Sink Toward 52-Week Low
  • Ionis Q3: Revenue $242.7M, Net Loss $110.0M; TRYNGOLZA Guidance Cut and Pelacarsen Royalty Write-Down

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$943.71M
Net Income
-$381.39M
Diluted EPS
-$2.38
Op. Cash Flow
-$268.58M
Free Cash Flow
-$320.03M
Gross Profit
$927.8M
Operating Income
-$381.68M
Cash & Equivalents
$372.26M
Total Debt
$28.12M
Debt / Equity
0.06×
Net Margin
-40.4%
Shares Outstanding
163.3M sh
Source: 10-K · filed 2026-02-26 · accession 0000874015-26-000115

Short Interest & Short Volume

8.41 days to cover

FINRA reported short interest of 21,165,846 shares in IONS as of the October 30, 2026 settlement, a 2.5% increase from the prior period — about 8.4 days to cover at its recent average daily volume. On November 20, 2026, 50.0% of IONS volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)21,165,846 shares as of October 30, 2026
Change vs prior period▲ 2.5%
Days to cover8.41 at avg daily volume of 2,518,244
Daily short volume (FINRA facilities)50.0% of 827,051 shares on November 20, 2026
5-day average short volume50.5%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with I →
$26.76 +0.68% today
52-week range · as of 2026-11-09 $26.76 – $86.74
Market cap
$4.43B
Volume
3.2M (0.8× avg)
3-mo avg 4.1M
Live data · 2026-11-21 23:38 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed IONS - Latest Insights

IONS
Nov 17, 2026, 4:45 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $26.93
Real-time Price: $26.76 info
Change: -$0.170 (-0.63%) info
Market Cap: $4.427B info
IONS
Nov 17, 2026, 3:03 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $28.02
Real-time Price: $26.76 info
Change: -$1.26 (-4%) info
Market Cap: $4.427B info
IONS
Nov 10, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $31.17
Real-time Price: $26.76 info
Change: -$4.41 (-14%) info
Market Cap: $4.427B info
IONS
Nov 09, 2026, 11:01 AM EST
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $28.67
Real-time Price: $26.76 info
Change: -$1.90 (-7%) info
Market Cap: $4.427B info
IONS
Nov 09, 2026, 8:33 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $31.50
Real-time Price: $26.76 info
Change: -$4.74 (-15%) info
Market Cap: $4.427B info
IONS
Nov 09, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $37.00
Real-time Price: $26.76 info
Change: -$10.24 (-28%) info
Market Cap: $4.427B info
IONS
Nov 09, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $37.00
Real-time Price: $26.76 info
Change: -$10.24 (-28%) info
Market Cap: $4.427B info
IONS
Oct 23, 2026, 1:41 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $42.93
Real-time Price: $26.76 info
Change: -$16.17 (-38%) info
Market Cap: $4.427B info
IONS
Oct 20, 2026, 9:20 PM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $45.20
Real-time Price: $26.76 info
Change: -$18.44 (-41%) info
Market Cap: $4.427B info
IONS
Oct 16, 2026, 6:45 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $43.56
Real-time Price: $26.76 info
Change: -$16.80 (-39%) info
Market Cap: $4.427B info
IONS
Sep 23, 2026, 1:00 AM EDT
Source: BusinessWire
Importance Score:
9
Price at Filing: $45.75
Real-time Price: $26.76 info
Change: -$18.99 (-42%) info
Market Cap: $4.427B info
IONS
Sep 22, 2026, 8:36 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $46.42
Real-time Price: $26.76 info
Change: -$19.66 (-42%) info
Market Cap: $4.427B info
IONS
Sep 04, 2026, 4:41 PM EDT
Source: BusinessWire
Importance Score:
9
Price at Filing: $54.00
Real-time Price: $26.76 info
Change: -$27.24 (-50%) info
Market Cap: $4.427B info
IONS
Sep 04, 2026, 6:01 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $59.00
Real-time Price: $26.76 info
Change: -$32.24 (-55%) info
Market Cap: $4.427B info
IONS
Sep 03, 2026, 4:02 PM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $58.13
Real-time Price: $26.76 info
Change: -$31.37 (-54%) info
Market Cap: $4.427B info
IONS
Jul 29, 2026, 5:05 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $53.06
Real-time Price: $26.76 info
Change: -$26.30 (-50%) info
Market Cap: $4.427B info
IONS
Jul 29, 2026, 7:31 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $56.49
Real-time Price: $26.76 info
Change: -$29.73 (-53%) info
Market Cap: $4.427B info
IONS
Jul 29, 2026, 7:00 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $56.09
Real-time Price: $26.76 info
Change: -$29.33 (-52%) info
Market Cap: $4.427B info
IONS
Jul 09, 2026, 2:55 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $64.50
Real-time Price: $26.76 info
Change: -$37.74 (-59%) info
Market Cap: $4.427B info
IONS
Jul 09, 2026, 2:10 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $86.14
Real-time Price: $26.76 info
Change: -$59.38 (-69%) info
Market Cap: $4.427B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets